Allostera Pharma

New class of pre-clinical drugs, called Allosteramers primarily focused on inflammation and autoimmunity

placeMontreal, Montreal, Canada calendar_todayFounded 2006 language allostera.com

Innovation

1 patent family — focus: Chemistry & metallurgy; filing pace dormant. Cited 18 times.

Investor mix

4 investors on record; lead investors include BDC, Genesys Capital, GO Capital Asset Management, Inovia Capital.

Investor typeCountShare
Venture capital250%
Other / undisclosed250%
Coming soon